Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

The present disclosure provides an elastase inhibitor prodrug and use thereof, being a compound of formula I or a pharmaceutically acceptable salt, ester, isomer or solvate thereof, prodrugs or isotopically labeled compound. Compared with the compound 52 (control example) in WO 2018/175173 A1, the compound disclosed herein has the advantages of high pulmonary exposure and long half-life. The prodrugs of the present disclosure significantly increase the concentration and residence time of the active compound (control example) in the lungs with significant improvements in pharmacokinetics in vivo compared to the control example.

##STR00001##

A spherical organic nano boron crosslinker with a PAMAM core and a preparation method thereof, and a gel fracturing fluid. A chemical structure of the spherical organic nano boron crosslinker is shown as follows: ##STR00001##
In the formula, n=0, 1, 2 or 3; and ##STR00002##

Provided are a compound represented by specific chemical formula, an antireflection film including the same, and a display device including the antireflection film.

An organic light-emitting device includes a first electrode; a second electrode; and an organic layer between the first electrode and the second electrode. The organic layer includes an emission layer. The emission layer includes a first compound, a second compound, and a third compound. The first compound is represented by Formula 1, the second compound is represented by Formula 2, the third compound is represented by Formula 3, and the first compound and the second compound are different from each other. ##STR00001##

A solvent-free mixture of a crude lithium borate salt and lithium hydride, wherein the lithium hydride is at least 0.001 wt. % and at most 10 wt. %, relative to the weight of crude lithium borate salt, wherein the mixture has a water content of at most 100 μmol/g and an acid content of at most 10 μmol H.sup.+/g of crude lithium borate salt, method for producing the same, and use thereof for battery electrolytes.

Provided herein are compounds that are broad-spectrum protein kinase binding agents, detectable tracers comprising such compounds, and method of use thereof for the detection of protein kinases.

A series of new macrocycles and cage-like molecules are obtained in a high yield from a bis-(2,4-dialkoxyphenyl)arene (naphthalene, anthracene, pyrene, porphyrin, etc.) or a tris-(2,4-dialkoxyphenyl)arene (benzene, sym-tribenzobenzene) and paraformaldehyde under the catalysis of a Lewis acid. In addition, perhydroxybiphenylarenes (tetrabiphenyl trimer, naphthalene dimer, etc.) can be obtained by means of demethylation, and a variety of water-soluble derivatives can be obtained by further modification, with same exhibiting a good bond ability for guest molecules (purpurine, etc.). Moreover, the functional group introduced into the backbone enables the macrocycle to have excellent adsorption and separation capabilities and a photophysical property. The macrocyclic and cage-like molecules have commercially available raw materials, are simple to synthesize, have a high yield, and are convenient to modify, such that same have wide application prospects in gas adsorption and separation, facilitate performance improvement of luminescent materials, perform adsorption of water-soluble toxic substances, etc.

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

Provided are a novel boron-containing compound and an electrolyte solution additive for a secondary battery including the same. The electrolyte solution for a secondary battery provided in one embodiment includes the novel boron-containing compound, thereby suppressing the decomposition of an electrolyte solution to improve the capacity and the life characteristics of a battery.